Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients – a pilot study

References

• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Ninan MJ, Wadhwa PD, Gupta P. Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma. 2011;52:360–373.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Coutinho R, Clear AJ, Owen A, et al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res. 2013;19:6686–6695.
   PubMed Web of Science ®Google Scholar
• Culpin RE, Sieniawski M, Angus B, et al. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. Histopathology. 2013;63:788–801.
   PubMed Web of Science ®Google Scholar
• Read JA, Koff JL, Nastoupil LJ, et al. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014;14:460–467e2.
   PubMed Web of Science ®Google Scholar
• Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34:327–340.
   PubMed Web of Science ®Google Scholar
• Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3460–3467.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452–3459.
   PubMed Web of Science ®Google Scholar
• Armitage EG, Barbas C. Metabolomics in cancer biomarker discovery: current trends and future perspectives. J Pharm Biomed Anal. 2014;87:1–11.
   PubMed Web of Science ®Google Scholar
• Psychogios N, Hau DD, Peng J, et al. The human serum metabolome. PLoS One. 2011;6:e16957.
   PubMed Web of Science ®Google Scholar
• Nagana Gowda GA, Gowda YN, Raftery D. Expanding the limits of human blood metabolite quantitation using NMR spectroscopy. Anal Chem. 2015;87:706–715.
   PubMed Web of Science ®Google Scholar
• Wen H, Yoo SS, Kang J, et al. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol. 2010;52:228–233.
   PubMed Web of Science ®Google Scholar
• Xu X, Cheng S, Ding C, et al. Identification of bile biomarkers of biliary tract cancer through a liquid chromatography/mass spectrometry-based metabolomic method. Mol Med Rep. 2015;11:2191–2198.
   PubMed Web of Science ®Google Scholar
• Jin H, Qiao F, Chen L, et al. Serum metabolomic signatures of lymph node metastasis of esophageal squamous cell carcinoma. J Proteome Res. 2014;13:4091–4103.
   PubMed Web of Science ®Google Scholar
• Bansal N, Gupta A, Mitash N, et al. Low- and high-grade bladder cancer determination via human serum-based metabolomics approach. J Proteome Res. 2013;12:5839–5850.
   PubMed Web of Science ®Google Scholar
• Chen WL, Wang JH, Zhao AH, et al. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood. 2014;124:1645–1654.
   PubMed Web of Science ®Google Scholar
• Jobard E, Pontoizeau C, Blaise BJ, et al. A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Lett. 2014;343:33–41.
   PubMed Web of Science ®Google Scholar
• Tenori L, Oakman C, Claudino WM, et al. Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Mol Oncol. 2012;6:437–444.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Savorani F, Tomasi G, Engelsen SB. icoshift: a versatile tool for the rapid alignment of 1D NMR spectra. J Magn Reson. 2010;202:190–202.
   PubMed Web of Science ®Google Scholar
• Tomasi G, Savorani F, Engelsen SB. icoshift: an effective tool for the alignment of chromatographic data. J Chromatogr A. 2011;1218:7832–7840.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0 – The Human Metabolome Database in 2013. Nucleic Acids Res. 2013;41:D801–D807.
   PubMed Web of Science ®Google Scholar
• Ludwig C, Easton J, Lodi A, et al. Birmingham Metabolite Library: a publicly accessible database of 1-D 1H and 2-D 1H J-resolved NMR spectra of authentic metabolite standards (BML-NMR). Metabolomics. 2012;8:8–18.
   Web of Science ®Google Scholar
• Salek RM, Steinbeck C, Viant MR, et al. The role of reporting standards for metabolite annotation and identification in metabolomic studies. Gigascience. 2013;2:13.
   PubMed Web of Science ®Google Scholar
• Wold S, Esbensen K, Geladi P. Proceedings of the Multivariate Statistical Workshop for Geologists and Geochemists Principal Component Analysis. Chemometr Intell Lab Syst. 1987;2:37–52.
   Web of Science ®Google Scholar
• Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemometr. 2002;16:119–128.
   Web of Science ®Google Scholar
• Bylesjö M, Rantalainen M, Cloarec O, et al. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometr. 2006;20:341–351.
   Web of Science ®Google Scholar
• Deja S, Porebska I, Kowal A, et al. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. J Pharm Biomed Anal. 2014;100:369–380.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Taylor SL, Barupal DK, et al. Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography time-of-flight mass spectrometry. Metabolites. 2015;5:192–210.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jin H, Guo X, et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1)H nuclear magnetic resonance-based metabolomic profiles. Clin Biochem. 2012;45:1064–1069.
   PubMed Web of Science ®Google Scholar
• Fahrmann JF, Kim K, DeFelice BC, et al. Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. Cancer Epidemiol Biomarkers Prev. 2015;24:1716–1723.
   PubMed Web of Science ®Google Scholar
• Nishiumi S, Kobayashi T, Ikeda A, et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One. 2012;7:e40459.
   PubMed Web of Science ®Google Scholar
• Yu L, Aa J, Xu J, et al. Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011;26:1290–1297.
   PubMed Web of Science ®Google Scholar
• Maeda J, Higashiyama M, Imaizumi A, et al. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer. 2010;10:690.
   PubMed Web of Science ®Google Scholar
• Loser C, Folsch UR, Paprotny C, et al. Polyamines in human gastric and esophageal cancer. Scand J Gastroenterol. 1989;24:1193–1199.
   PubMed Web of Science ®Google Scholar
• Loser C, Folsch UR, Paprotny C, et al. Polyamine concentrations in pancreatic tissue, serum, and urine of patients with pancreatic cancer. Pancreas. 1990;5:119–127.
   PubMed Web of Science ®Google Scholar
• Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208:714–723.
   PubMed Web of Science ®Google Scholar
• Choi WWL, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494–5502.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828–1837.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood. 2011;118:1350–1358.
   PubMed Web of Science ®Google Scholar
• Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33:2848–2856.
   PubMed Web of Science ®Google Scholar
• Villasenor A, Kinross JM, Li JV, et al. 1H NMR global metabolic phenotyping of acute pancreatitis in the emergency unit. J Proteome Res. 2014;13:5362–5375.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Holmes E, Kinross JM, et al. Metabolic phenotyping in clinical and surgical environments. Nature. 2012;491:384–392.
   PubMed Web of Science ®Google Scholar